Gastrointestinal Stromal Tumors: Response Evaluation Criteria of CHOI through Computed Tomography
Keywords:
GIST (gastrointestinal stromal tumor), RECIST 11, response evaluation choi criteria, computed tomography
Abstract
A CT scan is a tool that has been demonstrated to be optimal for response evaluation in gastrointestinal stroma tumors that undergo targeted therapy. In this study, response and evaluation of gastrointestinal stroma tumors were compared with the use of targeted therapy according to CHOI criteria in Oncology Siglo XXI Hospital patients. Materials and Methods: A retrospective study from January 2009 to January 2014 in patients with a confirmed diagnosis with access to CT scan; a response to the treatment was observed according to CHOI criteria. Results: A total of 31 patients were enrolled in this study, 61% received targeted therapy with Imatinib and 38% received second-line Imatinib and Sunitinib treatment, with a minimum follow up of 6 months and a maximum of one year. According to CHOI criteria, 45.2% of the patients reached CR, 19.4% had SD, 19.4% reached PR, and 16.1% had PD. Conclusions: Tumor response assessment according to CHOI criteria was useful for the evaluation of molecular targeted therapy in patients with GIST tumor.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
G. Medrano, V. Torres, R. González (2008) Características clínicas de los tumores del estroma gastrointestinal. 30, 1-2008.
T. Muñoz, T. Sabah, R. Navarro, cols (2006) Tumores del estroma gastrointestinal (GIST): Revisión de la literatura. 17(1), 43-51.
Soyer Bensimhon D, Boudiaf cols (2009) Imaging Of Gastrointestinal Stromal Tumors. 90(4), 469-480.
Brian Druker, Nicholas Lydon (2000) Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. 105(1), 3-7. https://doi.org/10.1172/jci9083
Hui C, Yun Z, Ming W, Dan-ping SH (2010) Pronosticanalysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. 132(2), 131-136.
I. Rabin, B. Chikman, R. Lavy (2009) Gastrointestinal Stromal Tumors: A 19 Experience. 12(11), 98-102.
Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. 3, 557-86.
Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M (2003) From the Archives of the AFIP Gastrointestinal Stromal Tumors: Radiologic Features with Pathologic Correlation. 23, 283-304.
Bhakta Nowain A, Pais S, pathogenesis, treatment strategies, prognosis (2005) Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. 20(6), 818-24.
A. Pérez-Morales, I. Ruiz-Juárez, D. Roesch, cols (2007) Tumores del estroma gastrointestinal. Presentación de una serie de tres casos de localización gástrica. 29(1), 50-53.
Choi H, Charnsangavej C, Faria SC (2007) Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. 25(13), 1753-1759. https://doi.org/10.1200/jco.2006.07.3049
T. Toyokawa, Y. Yamashita, A. Yamamoto (2014) Clinical experience of Imatinib mesylate for metastatic or recurrente gastrointestinal stromal tumor. 41(1), 55-8.
Haesun Choi (2007) Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. 25(13), 1753-1759. https://doi.org/10.1200/jco.2006.07.3049
Published
2015-07-20
Issue
Section
License
Copyright (c) 2015 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.